Molecular imaging in experimental pulmonary fibrosis reveals that nintedanib unexpectedly modulates CCR2 immune cell infiltration
Authors:
Open Access
- 7 November 2024
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 110, 105431
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Interstitial Lung DiseaseJAMA, 2024
- Human inherited CCR2 deficiency underlies progressive polycystic lung diseaseCell, 2023
- Early, non-invasive detection of radiation-induced lung injury using PET/CT by targeting CXCR4European Journal of Nuclear Medicine and Molecular Imaging, 2023
- Preclinical Mouse Model of Silicosis2023
- Clinical Molecular Imaging of Pulmonary CXCR4 Expression to Predict Outcome of Pirfenidone Treatment in Idiopathic Pulmonary FibrosisChest, 2021
- Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)European Journal of Nuclear Medicine and Molecular Imaging, 2019
- Clinical Pharmacokinetics and Pharmacodynamics of NintedanibClinical Pharmacokinetics, 2019
- Reduced Supply of Monocyte-Derived Macrophages Leads to a Transition from Nodular to Diffuse Lesions and Tissue Cell Activation in Silica-Induced Pulmonary Fibrosis in MiceThe American Journal of Pathology, 2015
- C‐C chemokine receptor 2 (CCR2) deficiency improves bleomycin‐induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage‐derived matrix metalloproteinasesThe Journal of Pathology, 2004
- CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosisCytokine, 2003